The collaboration between pharmaceutical and diagnostics companies is essential for advancing precision medicine through companion diagnostics, which accurately identify tumor responses to therapies. This approach enhances patient-specific treatment, thus facilitating a significant increase in therapy effectiveness. By integrating artificial intelligence and computational pathology, diagnostics can become more accessible and efficient, particularly in underserved regions. Overcoming barriers such as infrastructure and regulatory challenges, while shifting focus from monetization to patient-centric solutions, is crucial for democratizing access to care.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.